{"schema":"rootz.ai/filing-signals/v1","query":{"ticker":"PLYX","limit":50},"count":12,"signals":[{"ticker":"PLYX","company":"Polaryx Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":31,"context":"and adult-onset, with infantile Tay-Sachs disease being the most severe. Symptom onsets begin within the first sixmonths of life, with symptoms such as motor weakness, developmental delay, and the hallmark cherry-red spot visible in the retina. Compared to the infantile variant, the juvenile and adult-onset forms of the disease progress more slowly and may present psychiatric symptoms during adultho","filed_date":"2026-03-24","accession":"0001213900-26-033064","full_text":"https://origin.rootz.global/static/filing/0001213900-26-033064.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PLYX","company":"Polaryx Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":62,"context":"of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement and civil or criminal penalties. Any agency or judicial enforcement action could have a material adverse effect on our company and our products or product candidates. ** ** 40 ** *U.S.Government Regulation* In the UnitedStates, the FDA regulates drugs under the Federal Food, Drug, and Cosmetic Act (FDCA) and i","filed_date":"2026-03-24","accession":"0001213900-26-033064","full_text":"https://origin.rootz.global/static/filing/0001213900-26-033064.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PLYX","company":"Polaryx Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":31,"context":"conducting or completing clinical trials. In part because of this lack of experience, we cannot be certain that our planned clinical trials will begin on time, meet our anticipated timelines for enrollment and data analysis, or be completed on time, if at all. In addition, we have not yet demonstrated our ability to successfully complete late-stage clinical trials, obtain regulatory or marketing app","filed_date":"2026-01-27","accession":"0001213900-26-007973","full_text":"https://origin.rootz.global/static/filing/0001213900-26-007973.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PLYX","company":"Polaryx Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":41,"context":"her to invest in our common stock. The occurrence of one or more of the events or circumstances described in these risk factors, alone or in combination with other events or circumstances, may have a material adverse effect on our business, reputation, revenue, financial condition, results of operations and future prospects, in which event you could lose all or part of your investment. The risks and uncertainties descri","filed_date":"2026-01-27","accession":"0001213900-26-007973","full_text":"https://origin.rootz.global/static/filing/0001213900-26-007973.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PLYX","company":"Polaryx Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":31,"context":"conducting or completing clinical trials. In part because of this lack of experience, we cannot be certain that our planned clinical trials will begin on time, meet our anticipated timelines for enrollment and data analysis, or be completed on time, if at all. In addition, we have not yet demonstrated our ability to successfully complete late-stage clinical trials, obtain regulatory or marketing app","filed_date":"2025-11-21","accession":"0001213900-25-113249","full_text":"https://origin.rootz.global/static/filing/0001213900-25-113249.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PLYX","company":"Polaryx Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":41,"context":"her to invest in our common stock. The occurrence of one or more of the events or circumstances described in these risk factors, alone or in combination with other events or circumstances, may have a material adverse effect on our business, reputation, revenue, financial condition, results of operations and future prospects, in which event you could lose all or part of your investment. The risks and uncertainties descri","filed_date":"2025-11-21","accession":"0001213900-25-113249","full_text":"https://origin.rootz.global/static/filing/0001213900-25-113249.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PLYX","company":"Polaryx Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":69,"match_count":8,"context":"prospectus. 145 [Table of Contents](#TOC001) EXECUTIVE COMPENSATION Overview This section provides an overview of the material components of our executive compensation program each for the following named executive officers (collectively, our “NEOs”) during the fiscal year ended December 31, 2024. | Name |   | Title | | | Alex Yang |   | Chief Executive Officer | | | Andrew O","filed_date":"2025-11-21","accession":"0001213900-25-113249","full_text":"https://origin.rootz.global/static/filing/0001213900-25-113249.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PLYX","company":"Polaryx Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":61,"match_count":7,"context":"prospectus. 145 [Table of Contents](#TOC001) EXECUTIVE COMPENSATION Overview This section provides an overview of the material components of our executive compensation program each for the following named executive officers (collectively, our “NEOs”) during the fiscal year ended December 31, 2025. | Name |   | Title | | | Alex Yang |   | Chief Executive Officer | | | Lisa Bol","filed_date":"2026-01-27","accession":"0001213900-26-007973","full_text":"https://origin.rootz.global/static/filing/0001213900-26-007973.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PLYX","company":"Polaryx Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":32,"match_count":4,"context":"defined under the rules of the SEC. Item 11. Executive Compensation Overview This section provides an overview of the material components of our executive compensation program each for the following named executive officers (collectively, our NEOs) during the fiscal year ended December31, 2025. | Name | | Title | | | Alex Yang | | Chief Executive Officer | | | Lisa Bollinger | | Chief Medical Officer(1) | | |","filed_date":"2026-03-24","accession":"0001213900-26-033064","full_text":"https://origin.rootz.global/static/filing/0001213900-26-033064.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PLYX","company":"Polaryx Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":16,"match_count":2,"context":"ompany that occurs within sevenyears following the applicable date of grant. Vesting of the restricted stock units is contingent upon the recipients services to the Company through three or four installments on the first three or four anniversaries of the vesting commencement date. The change in control requirement represents a performance condition that is recognized when it is probable, and therefo","filed_date":"2026-08-13","accession":"0001213900-26-089118","full_text":"https://origin.rootz.global/static/filing/0001213900-26-089118.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PLYX","company":"Polaryx Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"restructuring","strength":8,"match_count":1,"context":"gment expenses.” In addition, the amendments enhance interim disclosure requirements, clarify circumstances in which an entity can disclose multiple segment measures of profit or loss, provide new segment disclosure requirements for entities with a single reportable segment, and contain other disclosure requirements. ASU 2023-07 is effective for the Company prospectively to all annual periods b","filed_date":"2026-01-27","accession":"0001213900-26-007973","full_text":"https://origin.rootz.global/static/filing/0001213900-26-007973.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"PLYX","company":"Polaryx Therapeutics, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"restructuring","strength":8,"match_count":1,"context":"gment expenses.” In addition, the amendments enhance interim disclosure requirements, clarify circumstances in which an entity can disclose multiple segment measures of profit or loss, provide new segment disclosure requirements for entities with a single reportable segment, and contain other disclosure requirements. ASU 2023-07 is effective for the Company prospectively to all annual periods b","filed_date":"2025-11-21","accession":"0001213900-25-113249","full_text":"https://origin.rootz.global/static/filing/0001213900-25-113249.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."}],"origin":{"leaf":"e56ebd9f2dd7624d33770b924cec3af96227da60951e303b4aa3373bcead46ae","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"0e9616300073268d7d4a60b5b25db011595dd3e58b7fbe82868d022c36a6bae3","parent":null,"source":"signal_search","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256() || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":11,"hourly_limit":500,"remaining":489,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}